Literature DB >> 8188738

Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion.

W Tomkowski1, M Szturmowicz, A Fijalkowska, S Filipecki, E Figura-Chojak.   

Abstract

Nine patients (seven men and two women), median age 57 years (range 40-68 years), with large malignant pericardial effusion confirmed by cytological examination, were treated with direct intrapericardial administration of cisplatin. After insertion of a polyurethane catheter, fluid was drained and cisplatin (10 mg in 20 ml normal saline) was instilled over 5 min during 5 consecutive days (total cisplatin dose: 50 mg). If fluid reaccumulation occurred the courses were repeated every 3 weeks. All of the patients achieved a complete therapeutic response (no more fluid reaccumulation). The median time of response was 2.8 months (range 1-24 months). Mild nausea occurred in two patients, supraventricular arrhythmia in one patient and infectious complications in one patient. Eight patients died because of disease progression without evidence of cardiac tamponade or stricture. Autopsy, performed in 7 cases, revealed neoplastic involvement of the pericardium in all of the patients, but pericardial effusion was seen in one patient only.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188738     DOI: 10.1007/bf01240144

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

1.  Phosphorus-32-colloidal chromic phosphate: treatment of choice for malignant pericardial effusion.

Authors:  J T Sprengelmeyer; R L McDermott
Journal:  J Nucl Med       Date:  1990-12       Impact factor: 10.057

2.  [2 cases of administration of cytostatics into the pericardial sac in patients with threatened cardiac tamponade in neoplasms].

Authors:  M Pawlicki; J Kowalczyk; B Zuchowska-Vogelgesang
Journal:  Nowotwory       Date:  1987 Oct-Dec

3.  Intrapericardial installation of radioactive chromic phosphate in malignant effusion.

Authors:  N Martini; A H Freiman; R C Watson; B S Hilaris
Journal:  AJR Am J Roentgenol       Date:  1977-04       Impact factor: 3.959

4.  Intrapericardial tetracycline for the management of cardiac tamponade secondary to malignant pericardial effusion.

Authors:  S Davis; S M Sharma; E D Blumberg; C S Kim
Journal:  N Engl J Med       Date:  1978-11-16       Impact factor: 91.245

5.  Intrapericardial bleomycin for the management of cardiac tamponade secondary to malignant pericardial effusion.

Authors:  M C Cormican; C R Nyman
Journal:  Br Heart J       Date:  1990-01

Review 6.  Malignant pericardial diseases: diagnosis and treatment.

Authors:  J Kralstein; W Frishman
Journal:  Am Heart J       Date:  1987-03       Impact factor: 4.749

7.  Intrapericardial instillation of platin in malignant pericardial effusion.

Authors:  M V Fiorentino; O Daniele; P Morandi; S M Aversa; C Ghiotto; A Paccagnella; A Fornasiero
Journal:  Cancer       Date:  1988-11-01       Impact factor: 6.860

8.  Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion.

Authors:  H Okamoto; T Shinkai; M Yamakido; N Saijo
Journal:  Cancer       Date:  1993-01-01       Impact factor: 6.860

9.  Successful therapy of peritoneal mesothelioma with intraperitoneal chemotherapy alone. A case report.

Authors:  M L Garcia Moore; N Savaraj; L G Feun; E Donnelly
Journal:  Am J Clin Oncol       Date:  1992-12       Impact factor: 2.339

10.  Intracavitary cisplatin in malignant cardiac tamponade.

Authors:  M Bindi; M Trusso; E Tucci
Journal:  Tumori       Date:  1987-04-30
View more
  5 in total

1.  New approaches to the management and treatment of malignant pericardial effusion.

Authors:  W Tomkowski; M Szturmowicz; A Fijałkowska; J Burakowski; S Filipecki
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

2.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

Authors:  Chiara Lestuzzi
Journal:  World J Cardiol       Date:  2010-09-26

Review 3.  [Treatment of malignant pericardial effusion].

Authors:  M Berg; A Heisel; D Ukena; H J Schäfers; H Schieffer
Journal:  Med Klin (Munich)       Date:  1997-12

4.  Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer.

Authors:  T Moriya; Y Takiguchi; H Tabeta; R Watanabe; H Kimura; K Nagao; T Kuriyama
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

5.  Large Pericardial Effusion-Diagnostic and Therapeutic Options, with a Special Attention to the Role of Prolonged Pericardial Fluid Drainage.

Authors:  Małgorzata Dybowska; Monika Szturmowicz; Katarzyna Błasińska; Juliusz Gątarek; Ewa Augustynowicz-Kopeć; Renata Langfort; Paweł Kuca; Witold Tomkowski
Journal:  Diagnostics (Basel)       Date:  2022-06-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.